Noah Hahn
Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Noah Hahn

Oncology
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, 
Baltimore, MD 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group.

Dr. Hahn is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Duke University Medical Center, Internal Medicine, 2003
Specialties
Oncology
Licenses
Internal Medicine in DC
Fellowships
Indiana University Health and Hospitals, Medical Oncology, 2006
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, Baltimore, MD 21287
Call: 410-955-6100
Other Locations
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
10803 Falls Road, Pavilion III STE 1500, Lutherville, MD 21093
Call: 410-583-2970

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: HER2/41BB Bispecific
Study Phase: Phase 1
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

156 Total Publications

Intratumoral expression of a composite B cell / CD8 T cell biomarker stratifies overall survival by ctDNA status and benefit from adjuvant immunotherapy in high risk, muscle invasive urothelial carcinoma.
Intratumoral expression of a composite B cell / CD8 T cell biomarker stratifies overall survival by ctDNA status and benefit from adjuvant immunotherapy in high risk, muscle invasive urothelial carcinoma.
Journal: The Journal of urology
Published: October 27, 2025
View All 156 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Heather D. Mannuel
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Heather D. Mannuel
Oncology | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Heather Mannuel is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mannuel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Prostate Cancer, and Renal Cell Carcinoma (RCC). Dr. Mannuel is currently accepting new patients.

Michael A. Carducci
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael A. Carducci
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Michael A. Carducci
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arif I. Hussain
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arif I. Hussain
Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arif Hussain is an Oncologist in Baltimore, Maryland. Dr. Hussain is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Prostate Cancer, and Familial Prostate Cancer. Dr. Hussain is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hahn's expertise for a condition
ConditionClose
  • Elite
  • Bladder Cancer
    Dr. Hahn is
    Elite
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Hahn is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Hahn is
    Elite
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Urothelial Cancer
    Dr. Hahn is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Hahn is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Hahn is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Hahn is
    Distinguished
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Hahn is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Hahn is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Clear Cell Sarcoma
    Dr. Hahn is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Hahn is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Prostate Cancer
    Dr. Hahn is
    Advanced
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Teratoma of the Mediastinum
    Dr. Hahn is
    Advanced
    . Learn about Teratoma of the Mediastinum.
    See more Teratoma of the Mediastinum experts
  • Testicular Cancer
    Dr. Hahn is
    Advanced
    . Learn about Testicular Cancer.
    See more Testicular Cancer experts
  • Wilms Tumor
    Dr. Hahn is
    Advanced
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • Experienced
  • Choriocarcinoma
    Dr. Hahn is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Dehydration
    Dr. Hahn is
    Experienced
    . Learn about Dehydration.
    See more Dehydration experts
  • Familial Prostate Cancer
    Dr. Hahn is
    Experienced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Hemolytic Transfusion Reaction
    Dr. Hahn is
    Experienced
    . Learn about Hemolytic Transfusion Reaction.
    See more Hemolytic Transfusion Reaction experts
  • Hypophosphatemia
    Dr. Hahn is
    Experienced
    . Learn about Hypophosphatemia.
    See more Hypophosphatemia experts
  • Lymphoid Hyperplasia
    Dr. Hahn is
    Experienced
    . Learn about Lymphoid Hyperplasia.
    See more Lymphoid Hyperplasia experts
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved